Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2015

01-10-2015 | Original Article

Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn’s Disease Treated Early with Thiopurines

Authors: Zubin Grover, Peter Lewindon

Published in: Digestive Diseases and Sciences | Issue 10/2015

Login to get access

Abstract

Background

Impact of first-line induction therapy on medium-term outcomes in the setting of early thiopurine (TP) use in children with Crohn’s disease has not been evaluated, in particular whether choice of exclusive enteral nutrition (EEN) over corticosteroids (CS) for induction impacts clinical outcomes at 12 and 24 months.

Aims and Methods

In this retrospective study, 89 children from our database with new diagnosis CD and follow-up of at least 2 years following induction with exclusive course of CS or EEN and early, dose-optimized TP (within 6 months from diagnosis) were evaluated. We compared steroid dependency (relapse <3 months of tapering first course CS or inability to wean <10 mg prednisolone), need for IFX, linear growth, and surgical resections over the first 2 years.

Results

Choice of EEN over CS induction was associated with reduced linear growth failure (7 vs. 26 %, p = 0.02), CS dependency (7 vs. 43 %, p = 0.002), and improved primary sustained response to IFX (86 vs. 68 %, p = 0.02). Combined CS/IFX-free remission and surgical resection rates were similar.

Conclusion

In the setting of early TP commencement, EEN induction is superior to CS induction for reducing growth failure, CS dependency, and loss of response to IFX over the first 2 years.
Appendix
Available only for authorised users
Literature
1.
go back to reference Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology. 2008;135:1106–1113.CrossRefPubMed Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology. 2008;135:1106–1113.CrossRefPubMed
2.
go back to reference Peneau A, Salleron J, Fumery M, et al. P137, Long term outcome of pediatric onset Crohn’s disease: A population based study, ECCO abstracts 2012. Peneau A, Salleron J, Fumery M, et al. P137, Long term outcome of pediatric onset Crohn’s disease: A population based study, ECCO abstracts 2012.
3.
go back to reference Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114–1122.CrossRefPubMed Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114–1122.CrossRefPubMed
4.
go back to reference Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953–961.CrossRefPubMed Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953–961.CrossRefPubMed
5.
go back to reference Whelan G, Farmer RG, Fazio VW, et al. Recurrence after surgery in Crohn’s disease. Relationship to location of disease (clinical pattern) and surgical indication. Gastroenterology. 1985;88:1826–1833.PubMed Whelan G, Farmer RG, Fazio VW, et al. Recurrence after surgery in Crohn’s disease. Relationship to location of disease (clinical pattern) and surgical indication. Gastroenterology. 1985;88:1826–1833.PubMed
6.
go back to reference Castile RG, Telander RL, Cooney D, et al. Crohn’s disease in children: assessment of the progression of disease, growth, and prognosis. J Pediatr Surg. 1980;15:462–469.CrossRefPubMed Castile RG, Telander RL, Cooney D, et al. Crohn’s disease in children: assessment of the progression of disease, growth, and prognosis. J Pediatr Surg. 1980;15:462–469.CrossRefPubMed
7.
go back to reference Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–1207.CrossRefPubMed Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–1207.CrossRefPubMed
8.
go back to reference Markowitz J, Grancher K, Kohn N, Lesser M, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000;119:895.CrossRefPubMed Markowitz J, Grancher K, Kohn N, Lesser M, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000;119:895.CrossRefPubMed
9.
go back to reference Jaspers G, Verkade H, Escher J, et al. Azathioprine maintains first remission in newly diagnosed pediatric Crohn’s disease. Inflamm Bowel Dis. 2006;12:831–836.CrossRefPubMed Jaspers G, Verkade H, Escher J, et al. Azathioprine maintains first remission in newly diagnosed pediatric Crohn’s disease. Inflamm Bowel Dis. 2006;12:831–836.CrossRefPubMed
10.
go back to reference Waters T, Kim M, Denson L, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 2014;146:383–391.CrossRef Waters T, Kim M, Denson L, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 2014;146:383–391.CrossRef
11.
go back to reference Riello L, Talbotec C, Garnier-Lengline H, et al. Tolerance and efficacy of azathioprine in pediatric Crohn’s disease. Inflamm Bowel Dis. 2011;17:2138–2143.CrossRefPubMed Riello L, Talbotec C, Garnier-Lengline H, et al. Tolerance and efficacy of azathioprine in pediatric Crohn’s disease. Inflamm Bowel Dis. 2011;17:2138–2143.CrossRefPubMed
12.
go back to reference Boyle B, Kappelman M, Colletti R, et al. Routine use of thiopurines in maintaining remission in paediatric Crohn’s disease. World J Gastroenterol. 2014;20:9185–9190.PubMedCentralPubMed Boyle B, Kappelman M, Colletti R, et al. Routine use of thiopurines in maintaining remission in paediatric Crohn’s disease. World J Gastroenterol. 2014;20:9185–9190.PubMedCentralPubMed
13.
go back to reference Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology. 2013;145:758–765.CrossRefPubMed Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn’s disease: a randomized controlled trial. Gastroenterology. 2013;145:758–765.CrossRefPubMed
14.
go back to reference Panes J, Lopez-Sanroma A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013;145:766–774.CrossRefPubMed Panes J, Lopez-Sanroma A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013;145:766–774.CrossRefPubMed
15.
go back to reference Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–1321.CrossRefPubMed Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–1321.CrossRefPubMed
16.
go back to reference Lee J, Escher J, Shuman M, et al. Final adult height of children with inflammatory bowel disease is predicted by parental height and patient minimum height Z-score. Inflamm Bowel Dis. 2010;16:1669–1677.PubMedCentralCrossRefPubMed Lee J, Escher J, Shuman M, et al. Final adult height of children with inflammatory bowel disease is predicted by parental height and patient minimum height Z-score. Inflamm Bowel Dis. 2010;16:1669–1677.PubMedCentralCrossRefPubMed
17.
go back to reference Cole TJ, Flegal KM, Nicholls D, et al. Body mass index cut offs to define thinness in children and adolescents: international survey. BMJ. 2007;335:194–202.PubMedCentralCrossRefPubMed Cole TJ, Flegal KM, Nicholls D, et al. Body mass index cut offs to define thinness in children and adolescents: international survey. BMJ. 2007;335:194–202.PubMedCentralCrossRefPubMed
18.
go back to reference Hyams J, Ferry G, Mandel F, et al. Development and validation of paediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439–447.PubMed Hyams J, Ferry G, Mandel F, et al. Development and validation of paediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439–447.PubMed
19.
go back to reference Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41:416–421.CrossRefPubMed Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41:416–421.CrossRefPubMed
20.
go back to reference Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–512.CrossRefPubMed Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60:505–512.CrossRefPubMed
21.
go back to reference Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162–169.CrossRefPubMed Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162–169.CrossRefPubMed
22.
go back to reference Grover Z, Muir R, Lewindon P. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn’s disease. J Gastroenterol. 2014;49:638–645.CrossRefPubMed Grover Z, Muir R, Lewindon P. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn’s disease. J Gastroenterol. 2014;49:638–645.CrossRefPubMed
23.
go back to reference Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7–27.CrossRefPubMed Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis. 2010;4:7–27.CrossRefPubMed
24.
go back to reference Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705–713.CrossRefPubMed Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705–713.CrossRefPubMed
25.
go back to reference Grover Z, Biron R, Carman N, et al. Predictors of response to infliximab in children with luminal Crohn’s disease. J Crohns Colitis. 2014;8:739–746.CrossRefPubMed Grover Z, Biron R, Carman N, et al. Predictors of response to infliximab in children with luminal Crohn’s disease. J Crohns Colitis. 2014;8:739–746.CrossRefPubMed
26.
go back to reference Sazuka S, Katsuno T, Nakagawa T, et al. Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn’s disease. Eur J Clin Nutr. 2012;66:1219–1223.CrossRefPubMed Sazuka S, Katsuno T, Nakagawa T, et al. Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn’s disease. Eur J Clin Nutr. 2012;66:1219–1223.CrossRefPubMed
29.
go back to reference Berni Canani R, Terrin G, Borrelli O, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis.. 2006;38:381–387.CrossRefPubMed Berni Canani R, Terrin G, Borrelli O, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn’s disease. Dig Liver Dis.. 2006;38:381–387.CrossRefPubMed
30.
go back to reference Cameron F, Gerasimidis K, Papangelou A, et al. Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn’s disease. Aliment Pharmacol Ther. 2013;37:622–629.CrossRefPubMed Cameron F, Gerasimidis K, Papangelou A, et al. Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn’s disease. Aliment Pharmacol Ther. 2013;37:622–629.CrossRefPubMed
Metadata
Title
Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn’s Disease Treated Early with Thiopurines
Authors
Zubin Grover
Peter Lewindon
Publication date
01-10-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3722-9

Other articles of this Issue 10/2015

Digestive Diseases and Sciences 10/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.